Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. / Klistorner, Alexander; Chai, Yi; Leocani, Letizia; Albrecht, Philipp; Aktas, Orhan; Butzkueven, Helmut; Ziemssen, Tjalf; Ziemssen, Focke; Frederiksen, Jette; Xu, Lei; Cadavid, Diego; RENEW MF-VEP Investigators.

I: CNS Drugs, Bind 32, Nr. 12, 12.2018, s. 1159-1171.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Klistorner, A, Chai, Y, Leocani, L, Albrecht, P, Aktas, O, Butzkueven, H, Ziemssen, T, Ziemssen, F, Frederiksen, J, Xu, L, Cadavid, D & RENEW MF-VEP Investigators 2018, 'Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential', CNS Drugs, bind 32, nr. 12, s. 1159-1171. https://doi.org/10.1007/s40263-018-0575-8

APA

Klistorner, A., Chai, Y., Leocani, L., Albrecht, P., Aktas, O., Butzkueven, H., ... RENEW MF-VEP Investigators (2018). Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs, 32(12), 1159-1171. https://doi.org/10.1007/s40263-018-0575-8

Vancouver

Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H o.a. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs. 2018 dec;32(12):1159-1171. https://doi.org/10.1007/s40263-018-0575-8

Author

Klistorner, Alexander ; Chai, Yi ; Leocani, Letizia ; Albrecht, Philipp ; Aktas, Orhan ; Butzkueven, Helmut ; Ziemssen, Tjalf ; Ziemssen, Focke ; Frederiksen, Jette ; Xu, Lei ; Cadavid, Diego ; RENEW MF-VEP Investigators. / Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. I: CNS Drugs. 2018 ; Bind 32, Nr. 12. s. 1159-1171.

Bibtex

@article{313b67f574c04d3c83873999ad22ff6f,
title = "Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential",
abstract = "BACKGROUND: Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.OBJECTIVE: MF-VEP testing was used to study changes in visual pathways in 48{\%} of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.METHODS: This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72{\%} female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71{\%} female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.RESULTS: A trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].CONCLUSION: Results from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment.REGISTRATION: ClinicalTrials.gov identifier NCT01721161.",
author = "Alexander Klistorner and Yi Chai and Letizia Leocani and Philipp Albrecht and Orhan Aktas and Helmut Butzkueven and Tjalf Ziemssen and Focke Ziemssen and Jette Frederiksen and Lei Xu and Diego Cadavid and {RENEW MF-VEP Investigators}",
year = "2018",
month = "12",
doi = "10.1007/s40263-018-0575-8",
language = "English",
volume = "32",
pages = "1159--1171",
journal = "C N S Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

AU - Klistorner, Alexander

AU - Chai, Yi

AU - Leocani, Letizia

AU - Albrecht, Philipp

AU - Aktas, Orhan

AU - Butzkueven, Helmut

AU - Ziemssen, Tjalf

AU - Ziemssen, Focke

AU - Frederiksen, Jette

AU - Xu, Lei

AU - Cadavid, Diego

AU - RENEW MF-VEP Investigators

PY - 2018/12

Y1 - 2018/12

N2 - BACKGROUND: Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.OBJECTIVE: MF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.METHODS: This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.RESULTS: A trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].CONCLUSION: Results from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment.REGISTRATION: ClinicalTrials.gov identifier NCT01721161.

AB - BACKGROUND: Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.OBJECTIVE: MF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.METHODS: This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.RESULTS: A trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].CONCLUSION: Results from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment.REGISTRATION: ClinicalTrials.gov identifier NCT01721161.

U2 - 10.1007/s40263-018-0575-8

DO - 10.1007/s40263-018-0575-8

M3 - Journal article

C2 - 30267385

AN - SCOPUS:85054290767

VL - 32

SP - 1159

EP - 1171

JO - C N S Drugs

JF - C N S Drugs

SN - 1172-7047

IS - 12

ER -

ID: 209805800